BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 21087107)

  • 1. Use of attenuated paramyxoviruses for cancer therapy.
    Lech PJ; Russell SJ
    Expert Rev Vaccines; 2010 Nov; 9(11):1275-302. PubMed ID: 21087107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes.
    Pühler F; Willuda J; Puhlmann J; Mumberg D; Römer-Oberdörfer A; Beier R
    Gene Ther; 2008 Mar; 15(5):371-83. PubMed ID: 18200068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.
    Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF
    Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virus combinations and chemotherapy for the treatment of human cancers.
    Kumar S; Gao L; Yeagy B; Reid T
    Curr Opin Mol Ther; 2008 Aug; 10(4):371-9. PubMed ID: 18683102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Progress in using Newcastle disease virus for tumor therapy: a review].
    Wu Y; Hao J; Li D
    Sheng Wu Gong Cheng Xue Bao; 2010 Aug; 26(8):1031-6. PubMed ID: 21090105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrophage response to oncolytic paramyxoviruses potentiates virus-mediated tumor cell killing.
    Tan DQ; Zhang L; Ohba K; Ye M; Ichiyama K; Yamamoto N
    Eur J Immunol; 2016 Apr; 46(4):919-28. PubMed ID: 26763072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of oncolytic measles virus: promises and challenges.
    Galanis E
    Clin Pharmacol Ther; 2010 Nov; 88(5):620-5. PubMed ID: 20881957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Measles virus: a future therapeutic agent in oncology?].
    Touchefeu Y; Schick U; Harrington KJ
    Med Sci (Paris); 2012 Apr; 28(4):388-94. PubMed ID: 22549866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies.
    Ong HT; Hasegawa K; Dietz AB; Russell SJ; Peng KW
    Gene Ther; 2007 Feb; 14(4):324-33. PubMed ID: 17051248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
    Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
    Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
    Fournier P; Bian H; Szeberényi J; Schirrmacher V
    Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted release of oncolytic measles virus by blood outgrowth endothelial cells in situ inhibits orthotopic gliomas.
    Wei J; Wahl J; Nakamura T; Stiller D; Mertens T; Debatin KM; Beltinger C
    Gene Ther; 2007 Nov; 14(22):1573-86. PubMed ID: 17898797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling of cancer virotherapy with recombinant measles viruses.
    Bajzer Z; Carr T; Josić K; Russell SJ; Dingli D
    J Theor Biol; 2008 May; 252(1):109-22. PubMed ID: 18316099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo efficacy of systemic tumor targeting of a viral RNA vector with oncolytic properties using a bispecific adapter protein.
    Bian H; Wilden H; Fournier P; Peeters B; Schirrmacher V
    Int J Oncol; 2006 Dec; 29(6):1359-69. PubMed ID: 17088973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions.
    Liu TC; Kirn D
    Cancer Res; 2007 Jan; 67(2):429-32. PubMed ID: 17234747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic vaccinia virus: from bedside to benchtop and back.
    Thorne SH
    Curr Opin Mol Ther; 2008 Aug; 10(4):387-92. PubMed ID: 18683104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors.
    Yaacov B; Eliahoo E; Lazar I; Ben-Shlomo M; Greenbaum I; Panet A; Zakay-Rones Z
    Cancer Gene Ther; 2008 Dec; 15(12):795-807. PubMed ID: 18535620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apoptin enhances the oncolytic properties of Newcastle disease virus.
    Wu Y; Zhang X; Wang X; Wang L; Hu S; Liu X; Meng S
    Intervirology; 2012; 55(4):276-86. PubMed ID: 21865658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reovirus - possible therapy of cancer.
    Figova K; Hrabeta J; Eckschlager T
    Neoplasma; 2006; 53(6):457-62. PubMed ID: 17167712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of Vaccine-Strain Measles and Mumps Viruses Enhances Oncolytic Activity against Human Solid Malignancies.
    Son HA; Zhang L; Cuong BK; Van Tong H; Cuong LD; Hang NT; Nhung HTM; Yamamoto N; Toan NL
    Cancer Invest; 2018 Feb; 36(2):106-117. PubMed ID: 29485292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.